FDA approves lisocabtagene maraleucel (liso-cel or JCAR-017) a CAR-T cell therapy for relapsed or refractory large B-cell lymphoma Below is the letter we received with the details for this remarkable COVID inspired program. It contains links to a... Details
CALQUENCE met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukemia (CLL) This was a gutsy trial, a first of its kind head-to-head comparison between two Bruton Tyrosine Kinase (BTK) inhibitors, acalabrutinib... Details
COVID Patient Support Program Extension: Free Medication from Bristol Myer Squibb (BMS) Below is the letter we received with the details for this remarkable COVID inspired program. It contains links to a... Details
NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL... Details
Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients... Details
Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia Calquence (acalabrutinib) is a 2nd generation BTK inhibitor with a different side effect profile than ibrutinib. It is already approved... Details
NICE okays chemotherapy-free combination venetoclax plus obinutuzumab for all front-line patients with chronic lymphocytic leukaemia (CLL) NICE gives green light for chemotherapy-free combination of venetoclax plus obinutuzumab for all front-line patients with CLL ... Details
The LLS CLL Co-Pay Assistance Fund is Open! LLS may be able to help pay your insurance premiums and co-pays if you are in active treatment or are... Details
FDA Grants Fast Track Designation to Ublituximab Plus Umbralisib in Chronic Lymphocytic Leukemia With this fast track designation, the combination of ublituximab and umbralisib should move through the FDA's approval process more quickly,... Details
New approval for venetoclax for Acute Myeloid Leukemia (AML) The U.S. Food and Drug Administration (FDA) has granted full approval of venetoclax in combination with azacitidine, or decitabine, or... Details
